Cell Viability Assays: What Each Readout Really Detects
Few plate assays are run as often, or misread as often, as cell viability assays. The name suggests a direct count of living cells, but almost none of them count anything. Each one measures a proxy: enzyme activity, ATP content, membrane integrity or protease activity, and each proxy can move for reasons other than cell death. For anyone testing peptides in culture, understanding what a given kit actually detects is the difference between a clean result and a confident mistake. This guide sorts the main assay families by what they measure and shows how to choose and combine them.
Decide which question you are asking
Viability, cytotoxicity and proliferation often get used as if they were synonyms, yet they describe different events. Viability asks how many cells in the well are alive. Cytotoxicity asks how many were killed or damaged. Proliferation asks whether the population grew. A peptide that halts division without killing anything will lower a metabolic readout just as a toxic one would, because there are fewer cells at the end of the incubation. Deciding which question you are asking narrows the choice of assay before you open a catalogue.
How the main cell viability assays work
| Assay family | What is measured | Readout | Main caveat |
|---|---|---|---|
| Tetrazolium (MTT, MTS, XTT, WST) | Reduction of a dye by cellular dehydrogenases | Absorbance | Reflects metabolic rate, not cell number |
| Resazurin | Reduction of resazurin to fluorescent resorufin | Fluorescence | Also metabolic; long incubations over-reduce the dye |
| ATP luminescence | ATP content via a luciferase reaction | Luminescence | ATP drops fast after death but also under energy stress |
| LDH release | Lactate dehydrogenase leaked into the medium | Absorbance or fluorescence | Measures damage, not survival; serum contains LDH |
| Dye exclusion (trypan blue, propidium iodide) | Whether intact membranes keep a dye out | Counting or imaging | Lower throughput; timing sensitive |
| Live-cell protease | A protease active only in living cells | Fluorescence | Multiplexes well; signal decays with time |
Metabolic assays
Tetrazolium and resazurin methods rely on living cells reducing a substrate. They are inexpensive and easy to scale, which is why they dominate screening. Their weakness is that anything changing a cell’s redox state or mitochondrial activity changes the signal. A peptide that boosts metabolism can make a well look more viable than its neighbour even if the cell counts are identical.
ATP assays
ATP content correlates closely with the number of metabolically active cells, and luminescent kits are very sensitive, detecting small numbers of cells per well. They lyse the cells, so the well cannot be used again, and they share the metabolic caveat: an energy-depleting treatment lowers ATP without killing.
Membrane integrity assays
LDH release and dye exclusion look at the other side of the question, counting cells whose membranes have failed. They detect necrosis and late apoptosis well but can miss early apoptosis, where membranes stay intact for some time.
Interference from the test compound
Peptides and their formulation components can interact with the assay chemistry itself. A few checks catch most problems:
- Incubate the peptide with the assay reagent in cell-free wells. Any signal change means direct chemical interference.
- Check for colour or fluorescence in the peptide solution at the assay wavelengths.
- Test the vehicle alone at the highest concentration used. Solvents such as DMSO lower viability readouts on their own above low percentages.
- For luciferase-based readouts, confirm the compound does not inhibit the enzyme.
- Consider pH: acidic counter-ions such as trifluoroacetate can shift the pH of weakly buffered wells at high peptide concentrations.
Multiplexing gives a clearer picture
Because every method is a proxy, pairing two that measure different things makes interpretation much stronger. A common combination is a live-cell protease or resazurin readout followed by a cytotoxicity marker in the same well, or LDH from the medium followed by ATP from the lysed cells. If the metabolic signal falls while the damage signal stays flat, the treatment probably slowed growth or metabolism rather than killing cells. If both move, cell death is more likely.
Imaging-based counts with nuclear stains add a third, direct measure where the equipment is available.
Design choices that affect every result
- Seeding density: choose a density that stays in the linear range of the assay for the full incubation. Overgrown control wells compress the window.
- Time points: an early read may miss slow death; a late read may reflect nutrient exhaustion in controls.
- Controls: include untreated, vehicle, and a known cytotoxic reference on every plate, plus medium-only blanks.
- Replicates: run technical replicate wells, but base conclusions on independent experiments on different days.
- Plate layout: avoid edge wells or fill them with medium to limit evaporation effects.
Reading the result
Express results relative to the vehicle control on the same plate rather than to untreated wells from another run, and report the time point alongside every value. A statement such as “reduced resazurin signal by 40% at 48 hours” is honest about what was measured; “killed 40% of cells” usually is not, unless a membrane-integrity or counting method backs it up. Where a concentration series is run, fit the curve and report the concentration giving a half-maximal reduction with its confidence interval rather than picking a single concentration.
Consistent material across a viability series
Viability work is often the first screen in a larger programme, so the numbers get reused as reference points for months. If the peptide lot changes midway, a shift in apparent toxicity could come from a difference in purity or counter-ion content rather than the biology. Labs buying in volume can avoid that by reserving enough vials from one lot for the whole series.
On receipt, log every vial with its lot number and the cap and crimp colour that matches it to its certificate, and note storage location and temperature. Bulk Peptides products are third-party tested for purity by HPLC, and certificates are published for some products; keeping that record with the plate data makes any later discrepancy much easier to trace.
Bulk Peptides supplies research peptides for in-vitro laboratory study only. They are not for human or animal use, and this article discusses laboratory assay methods, not any other application.
